Clinic
Responsible Medical Solutions Corp
Responsible Medical Solutions Corp was paid $3.62M by Medicaid between Jan 2018 and Dec 2024, across 50 billing codes. Its largest line is 99204, doctor's office visit, new patient (more involved) — 28% of everything it billed.
33Billing provider infoRESPONSIBLE MEDICAL SOLUTIONS CORP
TEMECULA, CA 92590
TEMECULA, CA 92590
33aNPI1013163914assigned 08/11/2008
33bProvider typeMedical Specialty Clinic/Center
28Total paid$3.62M
24GClaims106,529
24DCodes billed50
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medical Specialty Clinic/Center providers in California
Rank by total paid#5 of 164
Median peer was paid$37K
This provider vs. median99×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,143 | $240K | |
| 2019 | 12,421 | $369K | |
| 2020 | 17,855 | $518K | |
| 2021 | 16,754 | $638K | |
| 2022 | 18,000 | $776K | |
| 2023 | 19,296 | $611K | |
| 2024incomplete | 14,060 | $466K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 28% | 14,847 | 14,750 | $1.02M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 25% | 6,658 | 6,469 | $910K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 19,827 | 18,261 | $738K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.8% | 1,989 | 1,885 | $101K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.7% | 1,717 | 1,715 | $99K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.6% | 5,105 | 4,478 | $94K |
| 71046 | Radiologic examination, chest; 2 views | 2.5% | 3,489 | 3,391 | $92K |
| 99205 | Prolong outpt/office vis | 2.4% | 1,085 | 1,084 | $87K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.2% | 1,409 | 1,363 | $79K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.7% | 2,557 | 2,433 | $62K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.3% | 1,377 | 1,369 | $48K |
| 96127 | 1.0% | 7,875 | 7,336 | $36K |
38 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,159 | $35K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,910 | $34K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,610 | $29K |
| 99000 | <1% | 7,100 | $25K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,355 | $17K |
| 73630 | <1% | 694 | $16K | |
| 93000 | <1% | 580 | $16K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,134 | $13K |
| 73610 | <1% | 515 | $12K | |
| 81003 | <1% | 6,078 | $12K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 294 | $10K |
| 81025 | <1% | 2,409 | $7K | |
| 73130 | <1% | 205 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,910 | $4K |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 590 | $3K |
| 73110 | <1% | 102 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 922 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,883 | $2K |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 51 | $2K |
| 99051 | <1% | 278 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 167 | $1K |
| 73562 | <1% | 53 | $1K | |
| 87081 | <1% | 195 | $1K | |
| 72100 | <1% | 26 | $780.04 | |
| 12001 | <1% | 12 | $692.90 | |
| 80053 | Comprehensive metabolic panel | <1% | 66 | $606.54 |
| 73030 | <1% | 12 | $298.41 | |
| 73560 | <1% | 14 | $244.79 | |
| 69209 | <1% | 13 | $177.08 | |
| 73140 | <1% | 12 | $170.21 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 666 | $137.38 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 101 | $44.25 |
| 82947 | <1% | 13 | $39.24 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 172 | $36.51 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 210 | $23.67 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 28 | $22.42 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14 | $1.12 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHUTZ, STEVEN (MANAGER)